Scriptlinkrx
SolutionsPharmaciesBlog
Log inGet started
Home/Blog/Compounded Tirzepatide with Cyanocobalamin (B12): What Providers Should Know

Compounded Tirzepatide with Cyanocobalamin (B12): What Providers Should Know

ScriptLinkRx Team·July 2, 2026·Updated November 13, 2026
For licensed healthcare providers. Educational content only — not medical advice. Compounded medications are not FDA-approved.

Compounded tirzepatide with cyanocobalamin (vitamin B12) is a pharmacy-prepared injectable that combines tirzepatide, a dual GIP/GLP-1 receptor agonist, with cyanocobalamin, a synthetic form of vitamin B12, in a single formulation. It is not an FDA-approved drug product; it is prepared by 503A compounding pharmacies pursuant to individual prescriptions under section 503A of the Federal Food, Drug, and Cosmetic Act. (503B outsourcing facilities cannot compound tirzepatide from bulk: it is on neither the 503B bulks list nor the FDA drug shortage list.)

This formulation sits inside one of the most actively evolving regulatory environments in compounding. Providers considering this formulation need to understand both what the combination is and where FDA currently draws the compliance lines.

September 2026 Enforcement Update

On September 18, 2026 the FDA issued a warning letter to Empower Pharmacy, one of the largest compounders of GLP-1 products, concluding that its tirzepatide/niacinamide and semaglutide/cyanocobalamin (B12) products remained essentially copies of the approved drugs despite the added ingredient. The reasoning applies to tirzepatide with cyanocobalamin in the same way: an added vitamin does not by itself take the product outside the copy analysis. Three points from the letter apply directly:

  • Volume is evidence. The FDA said the volume being produced suggested the claimed differences from the approved products were pretextual. Scale now counts against a formulation on its own, independent of the paperwork behind it.
  • Templates fail. The agency flagged boilerplate significant-difference language and prescriptions with no determination at all.
  • Platforms are in scope. The letter pointed to third-party platforms that offer prescribers pre-selected options.

This follows the FDA's April 1, 2026 clarification, which used semaglutide plus vitamin B12 as its example of a product it may treat as essentially a copy when the route matches and the strengths are within 10% of the commercial products. The sections below were updated in October 2026 to reflect both. For the full analysis, see FDA's September 2026 warning letter to Empower: what it means for clinics.

What Tirzepatide with B12 Is

Tirzepatide is a synthetic peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The FDA-approved versions of tirzepatide are Eli Lilly's Mounjaro (approved in 2022 for type 2 diabetes) and Zepbound (approved in 2023 for chronic weight management). Compounded tirzepatide products are distinct from these approved drugs: they have not undergone FDA premarket review for safety, effectiveness, or quality, and they are not therapeutically interchangeable with the branded products.

Cyanocobalamin is a synthetic, stable form of vitamin B12. FDA-approved cyanocobalamin injection products exist for the treatment of documented B12 deficiency states. In compounded tirzepatide formulations, cyanocobalamin appears as an added ingredient in the same vial — a combination that does not exist in any FDA-approved product. The safety and effectiveness of tirzepatide combined with cyanocobalamin has not been established, a point FDA has made explicitly about GLP-1 formulations containing added vitamins.

How Providers Use It in Practice

Clinics that order compounded tirzepatide with B12 are typically weight-management practices, med spas operating under physician oversight, and metabolic or longevity-focused clinics that run prescriber-supervised programs. In these settings, some providers prescribe combination formulations when they have identified — and documented — a patient-specific clinical reason that an FDA-approved tirzepatide product does not address.

It is worth stating plainly what that documentation burden means: the clinical rationale for including cyanocobalamin must be individualized to the patient, and the responsibility for that justification rests with the prescriber, not the pharmacy. A blanket practice of adding B12 to every tirzepatide prescription, without a patient-specific basis, is precisely the pattern FDA has questioned in its public statements on compounded GLP-1 drugs. Providers should treat the additive as a clinical decision requiring chart support, not a default formulation choice.

Forms and Combinations Available Through Compounding

Compounding pharmacies that prepare tirzepatide-based formulations generally offer them as sterile injectable solutions in multi-dose vials, dispensed with prescriber-directed instructions. Within that category, several variations exist across the market:

  • Tirzepatide with cyanocobalamin (B12) — the formulation discussed here.
  • Tirzepatide with pyridoxine (B6) — covered in our companion article on compounded tirzepatide with B6.
  • Tirzepatide with levocarnitine — see compounded tirzepatide with L-carnitine.

The traditional rationale for compounding — patient-specific customization that an approved product cannot provide — is the legal foundation for all of these. Under section 503A, a compounded drug must be prepared for an identified individual patient based on a valid prescription, and, now that the tirzepatide shortage is resolved, it must not be "essentially a copy" of a commercially available FDA-approved drug. Whether an added ingredient such as cyanocobalamin takes a formulation outside the essentially-a-copy definition depends on whether the prescriber has determined that the change produces a clinical difference for that specific patient. The additive alone does not settle the question.

Regulatory Status and Provider Considerations

The regulatory posture of compounded tirzepatide has shifted substantially over the past two years. As of November 2026, the key facts are:

Shortage resolution. FDA removed tirzepatide from the drug shortage list and issued a declaratory order confirming the shortage resolved on December 19, 2024. During the shortage, 503A pharmacies and 503B outsourcing facilities could compound tirzepatide products that were essentially copies of Mounjaro and Zepbound. FDA provided short enforcement-discretion windows after the resolution — ending in March 2025 for both 503A pharmacies and 503B outsourcing facilities — after which copy-compounding restrictions applied in full.

Essentially-a-copy restrictions. With the shortage resolved, a 503A pharmacy may compound a tirzepatide formulation only if it is not essentially a copy of the approved products — which, in practical terms, requires a prescriber's documented determination that a modification (such as an added ingredient or a different formulation attribute) produces a significant clinical difference for the identified patient. FDA has publicly noted that some compounders add ingredients such as cyanocobalamin, pyridoxine, levocarnitine, or NAD to GLP-1 formulations, and has stated that the safety and effectiveness of these combinations have not been established. Providers should not assume the presence of B12 immunizes a prescription from copy analysis.

Proposed exclusion from the 503B bulks list. On May 1, 2026, FDA published a Federal Register notice proposing to exclude tirzepatide — along with semaglutide and liraglutide — from the list of bulk drug substances for which there is a clinical need under section 503B. FDA extended the comment period on that proposal to July 30, 2026; it has since closed, and no final decision had been published as of November 2026. Outsourcing facilities already cannot compound tirzepatide from bulk, because it is on neither the 503B bulks list nor the FDA drug shortage list; a final exclusion would keep it that way outside a future shortage.

Not FDA-approved, and not equivalent. No compounded tirzepatide product — with or without B12 — is FDA-approved. FDA has separately reported concerns with compounded GLP-1 products in the market, including dosing errors, unapproved salt forms of active ingredients, and adverse event reports. These concerns underscore why pharmacy selection and formulation verification matter as much as the prescribing decision itself.

State-level considerations. State boards of pharmacy regulate 503A compounding day to day, and several states have taken their own positions on GLP-1 copy compounding. Providers should confirm that any pharmacy partner is licensed in the state where the patient will receive the medication.

Sourcing and Quality: What to Ask a Compounding Pharmacy

Because compounded tirzepatide with B12 does not pass through FDA premarket review, quality assurance shifts to the pharmacy's own practices — and to the diligence of the clinic selecting that pharmacy. Questions worth asking before establishing a relationship:

  • API source and documentation. Is the tirzepatide active pharmaceutical ingredient sourced from an FDA-registered facility, and can the pharmacy produce a Certificate of Analysis for each lot of both tirzepatide and cyanocobalamin? Ask specifically whether the API is the base form used in the approved products rather than a salt form, which FDA has flagged as a distinct — and problematic — active ingredient.
  • Compounding standards. Does the pharmacy document compliance with USP <797> for sterile compounding (and USP <795>/<800> where applicable)?
  • Potency and sterility testing. Is each batch tested for potency, sterility, and endotoxin — and will the pharmacy share the results? Combination formulations add analytical complexity, so ask how the pharmacy verifies the stability of tirzepatide in the presence of cyanocobalamin.
  • Beyond-use dating. What beyond-use date is assigned, and is it supported by stability data specific to this combination rather than extrapolated from single-ingredient formulations?
  • Licensure and shipment. Is the pharmacy licensed in every state it ships to, and does it use cold-chain shipping validated for peptide products? FDA has received complaints about compounded GLP-1 products arriving outside recommended storage temperatures.
  • Copy-compliance process. How does the pharmacy document the prescriber's patient-specific rationale on each prescription? A pharmacy that asks for this documentation is protecting the prescriber as well as itself.

Frequently Asked Questions

Is compounded tirzepatide with B12 FDA-approved?

No. The FDA-approved tirzepatide products are Mounjaro and Zepbound, neither of which contains cyanocobalamin. Compounded formulations are not reviewed by FDA for safety, effectiveness, or quality and are not equivalent to the approved products.

Can 503A pharmacies still compound tirzepatide now that the shortage is over?

Only within the ordinary limits of section 503A. Since the shortage resolution in December 2024 and the expiration of FDA's enforcement-discretion windows in early 2025, a compounded tirzepatide product must not be essentially a copy of a commercially available approved drug. That generally requires a prescriber-documented, patient-specific clinical difference.

Does adding B12 automatically make the formulation "not a copy"?

No. The essentially-a-copy analysis turns on whether the prescriber determined that the modification produces a significant clinical difference for the individual patient. Adding cyanocobalamin as a routine practice, without individualized justification, does not resolve the copy question — and FDA has said that the safety and effectiveness of adding ingredients such as B12 to GLP-1 drugs have not been established.

What should the prescriber document?

At minimum, the patient-specific clinical reason the compounded combination is being prescribed instead of an FDA-approved tirzepatide product, recorded in the chart and communicated on or with the prescription. Many pharmacies will request this documentation before dispensing.

What happens if FDA finalizes the 503B bulks-list exclusion?

It would not change what clinics can order today: outsourcing facilities already cannot compound tirzepatide from bulk, because it is on neither the 503B bulks list nor the FDA drug shortage list; a final exclusion would keep it that way outside a future shortage. The proposal does not directly change 503A patient-specific compounding, which would remain governed by the essentially-a-copy framework. The comment period closed on July 30, 2026, and providers should monitor for the final determination.

Related Reading

  • Compounded tirzepatide with pyridoxine (B6)
  • Compounded tirzepatide with L-carnitine

Sources

  • FDA, Declaratory Order: Resolution of Shortages of Tirzepatide Injection (December 19, 2024)
  • FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
  • FDA, FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
  • FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
  • Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
  • Federal Register, Extension of Comment Period (June 26, 2026)
  • FDA, Understanding the Risks of Compounded Drugs
  • FDA: Warning Letters (search "Empower Clinic Services", September 18, 2026)
  • Frier Levitt: FDA Warning Letter Targets Compounded GLP-1 Products (September 2026)

Related Articles

Fact CheckGLP-1 & Metabolic

Compounded Tirzepatide with Pyridoxine (B6): A Provider's Guide

A provider guide to compounded tirzepatide with pyridoxine (B6): essentially-a-copy limits, the 2026 503B bulks proposal, and pharmacy quality questions.

Updated November 13, 2026·10 min read→
Fact CheckGLP-1 & Metabolic

Compounded Tirzepatide with L-Carnitine: A Provider's Overview

A provider guide to compounded tirzepatide with L-carnitine: regulatory status, FDA combination scrutiny, and sourcing questions for clinics.

Updated November 13, 2026·8 min read→

This content is intended for licensed healthcare providers and is for educational purposes only. It is not medical advice and is not an offer to sell, or a promotion of, any specific medication. Compounded medications are not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Prescribing decisions are the sole responsibility of the treating provider in accordance with federal and state law. Regulatory information is current as of November 2026 and subject to change.

LegitScript Certified

A 503A and 503B compounding pharmacy network for clinics, med spas and telehealth practices—one platform for ordering, e-prescribing and tracking.

Categories

  • Weight Management
  • Sexual Health
  • Hormone Therapy
  • Hair & Skin
  • General Health & Wellness

Solutions

  • 503A pharmacy ordering
  • 503B office-use ordering
  • TRT sourcing
  • Peptide sourcing
  • GLP-1 sourcing
  • For med spas
  • For telehealth companies

Main

  • Homepage
  • Request a demo
  • View Catalog
  • Partner pharmacies
  • Coverage by state
  • Blog

 

  • About
  • Privacy Policy
  • Terms and Services

© 2026 ScriptLinkRx. All rights reserved.

Back to top
Scriptlinkrx